Catalent announced the initiation of Phase II clinical trials of MGB Biopharma’s lead candidate, MGB-BP-3, an orally-dosed drug targeting the eradication of Clostridium difficile-associated diarrhea (CDAD). The two companies have collaborated to accelerate the drug formulation, manufacture and distribution of the drug.   Catalent’s services focused on the rapid development of a new tablet formulation leveraging its clinical supply network to distribute the resultant products for use in a U.S. Ph...